These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 22422504)
1. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504 [TBL] [Abstract][Full Text] [Related]
2. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors. Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054 [TBL] [Abstract][Full Text] [Related]
3. Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia. Lee YM; Kim GY; Pan CJ; Mansfield BC; Chou JY Mol Genet Metab Rep; 2015 Jun; 3():28-32. PubMed ID: 26937391 [TBL] [Abstract][Full Text] [Related]
4. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage. Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773 [TBL] [Abstract][Full Text] [Related]
5. Molecular biology and gene therapy for glycogen storage disease type Ib. Chou JY; Cho JH; Kim GY; Mansfield BC J Inherit Metab Dis; 2018 Nov; 41(6):1007-1014. PubMed ID: 29663270 [TBL] [Abstract][Full Text] [Related]
6. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420 [TBL] [Abstract][Full Text] [Related]
7. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes. Chou JY; Jun HS; Mansfield BC J Inherit Metab Dis; 2015 May; 38(3):511-9. PubMed ID: 25288127 [TBL] [Abstract][Full Text] [Related]
8. Liver-directed gene therapy for murine glycogen storage disease type Ib. Kwon JH; Lee YM; Cho JH; Kim GY; Anduaga J; Starost MF; Mansfield BC; Chou JY Hum Mol Genet; 2017 Nov; 26(22):4395-4405. PubMed ID: 28973635 [TBL] [Abstract][Full Text] [Related]
9. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Yiu WH; Lee YM; Peng WT; Pan CJ; Mead PA; Mansfield BC; Chou JY Mol Ther; 2010 Jun; 18(6):1076-84. PubMed ID: 20389290 [TBL] [Abstract][Full Text] [Related]
10. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review. Cho JH; Weinstein DA; Lee YM J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930 [TBL] [Abstract][Full Text] [Related]
11. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia. Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177 [TBL] [Abstract][Full Text] [Related]
12. Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice. Yiu WH; Pan CJ; Mead PA; Starost MF; Mansfield BC; Chou JY J Hepatol; 2009 Nov; 51(5):909-17. PubMed ID: 19376605 [TBL] [Abstract][Full Text] [Related]
13. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia. Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174 [TBL] [Abstract][Full Text] [Related]
14. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity. Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201 [TBL] [Abstract][Full Text] [Related]
15. The molecular basis of type 1 glycogen storage diseases. Chou JY Curr Mol Med; 2001 Mar; 1(1):25-44. PubMed ID: 11899241 [TBL] [Abstract][Full Text] [Related]
16. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703 [TBL] [Abstract][Full Text] [Related]
17. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy. Chou JY; Jun HS; Mansfield BC Nat Rev Endocrinol; 2010 Dec; 6(12):676-88. PubMed ID: 20975743 [TBL] [Abstract][Full Text] [Related]
18. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing. Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667 [TBL] [Abstract][Full Text] [Related]
19. Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia. Cho JH; Kim GY; Mansfield BC; Chou JY Biochem Biophys Res Commun; 2018 Apr; 498(4):925-931. PubMed ID: 29545180 [TBL] [Abstract][Full Text] [Related]
20. Recent development and gene therapy for glycogen storage disease type Ia. Chou JY; Kim GY; Cho JH Liver Res; 2017 Sep; 1(3):174-180. PubMed ID: 29576889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]